ReviewSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society2026
Rhein and its derivatives: potential anti-tumor drugs and corresponding targeted mechanism.
Review in Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Cancer remains a major global health threat with high morbidity and mortality, and clinical treatment is plagued by drug resistance, poor efficacy and severe side effects, driving the search for novel anti-tumor agents from natural products. Rhein, a natural anthraquinone abundant in Rheum palmatum and other medicinal plants, has emerged as a promising anti-tumor phytochemical due to its diverse pharmacological activities and multi-target action characteristics. This review systematically summarizes the natural distribution, chemical structure and structural modification strategies of rhein, and further elaborate the core targeted signaling pathways of rhein in exerting anti-tumor effects. Finally, we propose future research directions for rhein and its derivatives, including accelerating preclinical-to-clinical translation, optimizing structural modification and developing targeted delivery systems to reduce side effects and improve therapeutic efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.